Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET

ANAVEX2-73 demonstrates desirable PK/PD properties, describing the relationship between drug concentration and the effect observed Anavex is incorporating advanced Artificial Intelligence platform for the analysis of Phase 2a results with the aim to increase the chances of success in forthcoming Phase 2/3 study NEW YORK, October 12, 2017 – Anavex Life Sciences Corp. (Nasdaq: AVXL)…

Anavex®Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73

NEW YORK – September 5, 2017 – Anavex® Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that the United States Patent and Trademark Office has issued U.S. Patent Number 9,750,746 entitled “ANAVEX® 2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection.”  This patent provides the Company with intellectual property protection covering…

Money 1 1120 x 480

Anavex Reports Fiscal Third Quarter 2017 Financial Results

NEW YORK – August 7, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the fiscal quarter…

Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board

NEW YORK, NY – July 20, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Andrew J.…

Anavex Life Sciences to Present at Jefferies 2017 Global Healthcare Conference

NEW YORK — June 5, 2017 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that Christopher U. Missling, PhD, President…

Jefferies 2017 Global Healthcare Conference June 6-9

The Jefferies 2017 Global Healthcare Conference will be taking place June 6-9 in New York City. Following the success of last year’s event, with over 350 participating companies and 2,500 attendees, the conference will again feature an extensive range of public & private healthcare companies across the Biopharmaceuticals, Life Sciences, Healthcare Services, Healthcare IT and Medical Technology…